Houston, Texas–(Newsfile Corp. – March 11, 2020) – There’s a global march toward psychedelics for medicinal benefits.
While research has been off limits for decades, that’s quickly changing – and fast.
In recent years, the US FDA granted Breakthrough Therapy designation for Compass Pathways’ psilocybin treatment for depression. Denver, Oakland, and Santa Cruz just decriminalized the use of magic mushrooms. Chicago city leaders just passed a resolution supporting scientific and medicinal research, with a goal of decriminalization.
All on evidence the drug can improve obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression, anxiety, and even smoking.
Even more impressive, a study in the Journal of Psychopharmacology found that a single mushroom-based treatment can help improve the lives of cancer patients’ quality of life for nearly five years. This study builds on a 2016 study that provided treatments to 29 people suffering with life-threatening cancer, and were also diagnosed with depression or anxiety.
In addition, “Theoretically, psilocybin helps “loosen” the deeply-rooted patterns of thinking and behavior behind many of these mental disorders, according to King’s College London, as highlighted by CNN. It could ‘relax’ the parts of our brain that control these behaviors, thus allowing old patterns to change or fade. Patients who have received psilocybin have described coming down from the high with “new insights” and changed perspectives on their difficulties.”
Before long, big pharmaceutical companies will jump on the bandwagon.
At the moment, venture capitalists are jumping on the opportunity.
“I view the next five years as an absolutely golden window. There’s an opportunity to use relatively small amounts of money to have billions of dollars of impact and to affect millions of lives,” says angel investor Tim Ferriss, who has poured money into advancing research on the mushroom market, as quoted by Forbes. “There just aren’t that many opportunities that are so dramatically obvious.”
In addition, a good chunk of venture capital money has been raised to date from firms such as Field Trip Ventures, Numinus, and Tabula Rasa. Compass Pathways, raised $55 million from Thiel Capital and Galaxy Ventures’s Michael Novogratz, as well says Fortune.
Before long, big pharmaceutical companies could soon jump on the opportunity, too.
Read the full article at YahooFinance
